Profile data is unavailable for this security.
About the company
Lionco Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research, development, production, and sales of prescription chemical drugs. The Company’s main products cover four main categories: parenteral nutrition, anti-infectives, digestive system drugs, and cardiovascular and cerebrovascular drugs. The Company’s main products include Huperzine A for Injection, Cefmetazole Sodium for Injection, Cefuroxime Sodium for Injection, Cefuroxime Sodium for Injection, Alanyl-Glutamine Injection and others. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)430.61m
- Net income in CNY-118.38m
- Incorporated2003
- Employees436.00
- LocationLionco Pharmaceutical Group Co LtdMedicine Valley Industrial ParkNo. 16 Medicine Valley Erheng RoadNational Hi-tech Industrial Dvlpmnt ZneSHANNAN 856000ChinaCHN
- Phone+86 8 937830999
- Fax+86 8 937830888
- Websitehttp://www.lingkang.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hanshang Group Co Ltd | 1.04bn | -7.75m | 2.98bn | 2.24k | -- | 1.78 | -- | 2.88 | -0.0263 | -0.0263 | 3.51 | 5.66 | 0.2992 | 2.45 | 8.58 | 463,254.10 | -0.5073 | 1.38 | -0.911 | 2.59 | 44.80 | 61.66 | -1.70 | 3.79 | 0.3006 | -0.0194 | 0.300 | 17.52 | -15.41 | 0.3108 | -123.83 | -- | 4.52 | -- |
| Novoprotein Scientific Inc | 147.33m | -65.02m | 2.99bn | 566.00 | -- | 1.43 | -- | 20.30 | -0.9301 | -0.9301 | 2.10 | 29.82 | 0.0664 | 0.7531 | 2.20 | 260,302.10 | -2.93 | 4.36 | -3.02 | 4.58 | 62.01 | 74.11 | -44.13 | 26.35 | 24.75 | -- | 0.0227 | 24.96 | -16.73 | 28.80 | -523.69 | -- | 166.98 | -- |
| Shanghai Hile Bio-Technology Co Ltd | 246.35m | 171.34m | 3.05bn | 366.00 | 15.61 | 2.00 | -- | 12.38 | 0.2998 | 0.2998 | 0.3895 | 2.34 | 0.1438 | 0.8346 | 2.49 | 673,097.90 | 11.90 | 4.15 | 14.28 | 5.65 | 75.26 | 52.88 | 82.75 | 25.09 | 6.92 | -- | 0.0106 | 26.17 | 12.59 | -0.5053 | 172.28 | 69.73 | -26.47 | 67.20 |
| GuiZhou YiBai Pharmaceutical Co., Ltd. | 1.91bn | -234.63m | 3.14bn | 5.26k | -- | 1.31 | -- | 1.65 | -0.3003 | -0.3003 | 2.42 | 3.03 | 0.4764 | 1.43 | 9.21 | 362,458.80 | -6.27 | -0.973 | -8.33 | -1.31 | 58.70 | 72.00 | -13.17 | -1.65 | 1.25 | -10.11 | 0.2733 | -- | -22.92 | -8.34 | -406.79 | -- | -13.70 | -- |
| Shanghai Shenqi Pharmactcl Inv Mgt CoLtd | 1.88bn | 62.34m | 3.20bn | 1.27k | 52.94 | 1.44 | -- | 1.70 | 0.1186 | 0.1186 | 3.58 | 4.37 | 0.5981 | 4.66 | 5.41 | 1,487,675.00 | 1.85 | -0.6947 | 2.33 | -0.8656 | 44.60 | 53.83 | 3.10 | -1.04 | 2.57 | 31.84 | 0.0745 | -- | -12.48 | 1.23 | 25.24 | -3.20 | -13.91 | -- |
| Lionco Pharmaceutical Group Co Ltd | 430.61m | -118.38m | 3.25bn | 436.00 | -- | 4.41 | -- | 7.54 | -0.1609 | -0.1609 | 0.5928 | 1.02 | 0.3578 | 3.93 | 2.41 | 987,638.40 | -9.84 | -2.45 | -11.09 | -3.13 | 45.89 | 72.39 | -27.49 | -9.67 | 2.80 | -2.73 | 0.2791 | -- | 92.95 | -25.32 | 13.68 | -- | -4.03 | -- |
| Ginwa Enterprise Group Inc | 550.44m | 78.32m | 3.30bn | 588.00 | 40.93 | 2.08 | -- | 5.99 | 0.2157 | 0.2157 | 1.54 | 4.24 | 0.2885 | 4.56 | 4.97 | 936,120.60 | 4.04 | 0.839 | 4.86 | 0.9762 | 76.30 | 75.14 | 14.00 | 2.83 | 1.84 | -- | 0.0561 | 52.12 | 3.55 | -4.95 | 273.96 | 23.56 | 28.32 | 0.00 |
Data as of Mar 03 2026. Currency figures normalised to Lionco Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Gfund Management Co., Ltd.as of 30 Jun 2025 | 717.20k | 0.10% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 24.70k | 0.00% |
| Bank of Beijing Scotiabank Asset Management Co., Ltd.as of 30 Jun 2025 | 5.20k | 0.00% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2025 | 1.90k | 0.00% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
| Everbright PGIM Fund Management Co. Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 20 Feb 2026Source: FactSet Research Systems Inc.
